



Liste des publications IUCT-O/CRCT

Novembre 2022

Version du 01 décembre 2022

(IF 2021)

- 1) Angeles, M.A., Spagnolo, E., Cabarrou, B., Pérez-Benavente, A., Gil Moreno, A., Guyon, F., Rychlik, A., Migliorelli, F., Bataillon, G., Navarro, A.-S., Betrian, S., Ferron, G., Hernández, A., Martinez, A., 2022. **Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.** Int J Gynecol Cancer ijgc-2022-003985. <https://doi.org/10.1136/ijgc-2022-003985> (IF : 4.661 – cat B)
- 2) Angenendt, L., Röllig, C., Montesinos, P., Ravandi, F., Juliusson, G., Récher, C., Itzykson, R.A., Racil, Z., Wei, A.H., Schliemann, C., 2022. **Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.** Blood blood.2022018582. <https://doi.org/10.1182/blood.2022018582> (IF : 25.476 – cat A)
- 3) Bachelot, T., Cottu, P., Chabaud, S., Dalenc, F., Allouache, D., Delaloge, S., Jacquin, J.-P., Grenier, J., Venat Bouvet, L., Jegannathen, A., Campone, M., Del Piano, F., Debled, M., Hardy-Bessard, A.-C., Giacchetti, S., Mouret-Reynier, M.-A., Barthelemy, P., Kaluzinski, L., Mailliez, A., Legouffe, E., Sephton, M., Bliss, J., Canon, J.-L., Penault-Llorca, F., Lemonnier, J., Cameron, D., Andre, F., 2022. **Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.** J Clin Oncol 40, 3699–3708. <https://doi.org/10.1200/JCO.21.02179> (IF : 5.717 – cat A)
- 4) Benbassat, B., Cros, F., Dupret-Bories, A. & Meresse, T., 2022. **Cephalic vein transposition in head-and-neck reconstruction.** Eur Ann Otorhinolaryngol Head Neck Dis 139, 361–363. <https://doi.org/10.1016/j.anorl.2022.01.001> (IF : 2.665 – cat C)

- 5) Bidard, François-Clément, Hardy-Bessard, A.-C., Dalenc, F., Bachelot, T., Pierga, J.-Y., de la Motte Rouge, T., Sabatier, R., Dubot, C., Frenel, J.-S., Ferrero, J.M., Ladoire, S., Levy, C., Mouret-Reynier, M.-A., Lortholary, A., Grenier, J., Chakiba, C., Stefani, L., Plaza, J.E., Clatot, F., Teixeira, L., D'Hondt, V., Vegas, H., Derbel, O., Garnier-Tixidre, C., Canon, J.-L., Pistilli, B., André, F., Arnould, L., Pradines, A., Bièche, I., Callens, C., Lemonnier, J., Berger, F., Delaloge, S., PADA-1 investigators, 2022. **Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.** *Lancet Oncol* 23, 1367–1377. [https://doi.org/10.1016/S1470-2045\(22\)00555-1](https://doi.org/10.1016/S1470-2045(22)00555-1) (IF : 54.433 – cat A)

- 6) Bidard, Francois-Clement, Kaklamani, V.G., Neven, P., Streich, G., Montero, A.J., Forget, F., Mouret-Reynier, M.-A., Sohn, J.H., Taylor, D., Harnden, K.K., Khong, H., Kocsis, J., Dalenc, F., Dillon, P.M., Babu, S., Waters, S., Deleu, I., García Sáenz, J.A., Bria, E., Cazzaniga, M., Lu, J., Aftimos, P., Cortés, J., Liu, S., Tonini, G., Laurent, D., Habboubi, N., Conlan, M.G., Bardia, A., 2022. **Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.** *J Clin Oncol* 40, 3246–3256. <https://doi.org/10.1200/JCO.22.00338> (IF : 50.717 – cat A)

- 7) Bonvalot, S., Rutkowski, P.L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A.M., Mervoyer, A., Rastrelli, M., Moreno, V., Li, R.K., Tiangco, B.J., Herráez, A.C., Gronchi, A., Sy-Ortin, T., Hohenberger, P., de Baère, T., Cesne, A.L., Helfre, S., Saada-Bouزيد, E., Anghel, R.M., Kantor, G., Montero, A., Loong, H.H., Vergés, R., Kacso, G., Austen, L., Servois, V.F., Wardelmann, E., Dimitriu, M., Said, P., Lazar, A.J., Bovée, J.V.M.G., Péchoux, C.L., Pápai, Z., 2022. **Final Safety and Health-Related Quality of Life Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma.** *Int J Radiat Oncol Biol Phys* 114, 422–432. <https://doi.org/10.1016/j.ijrobp.2022.07.001> (IF : 8.013 – cat A)

- 8) Brett, V.-E., Lechevalier, N., Trimoreau, F., Dussiau, C., Dimicoli-Salazar, S., Coster, L., Luquet, I., Nadal, N., Ribourtout, B., Chapiro, E., Lefebvre, C., Tondeur, S., Balducci, E., Nguyen-Khac, F., Borie, C., Radford-Weiss, I., Barin, C., Eclache, V., Mansier, O., Bidet, A., Groupe Francophone de Cytogénétique Hématologique (GFCH), 2022. **The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia**

of unknown significance. Genes Chromosomes Cancer.
<https://doi.org/10.1002/gcc.23107> (IF : 4.263 – cat C)

- 9) Canali, A., Rieu, J.-B., Bain, B.J., 2022a. Peripheral CD5+ CD10+ B-cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation. Am J Hematol 97, 1489–1490. <https://doi.org/10.1002/ajh.26655> (IF : 13.265 – cat A)
- 10) Canali, A., Vergnolle, I., Bertoli, S., Largeaud, L., Nicolau, M.-L., Rieu, J.-B., Tavitian, S., Huguet, F., Picard, M., Bories, P., Vial, J.-P., Lechevalier, N., Béné, M.-C., Luquet, I., Mansat-De Mas, V., Delabesse, E., Recher, C., Vergez, F., 2022b. Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia. Clin Cancer Res CCR-22-2237. <https://doi.org/10.1158/1078-0432.CCR-22-2237> (IF : 13.801 – cat A)
- 11) Carrier, A., Desjobert, C., Lobjois, V., Rigal, L., Busato, F., Tost, J., Ensenyat-Mendez, M., Marzese, D.M., Pradines, A., Favre, G., Lamant, L., Lanfrancone, L., Etievant, C., Arimondo, P.B., Riond, J., 2022. Epigenetically regulated PCDHB15 impairs aggressiveness of metastatic melanoma cells. Clin Epigenetics 14, 156. <https://doi.org/10.1186/s13148-022-01364-x> (IF : 7.259 – cat B)
- 12) Cassioli, C., Patrussi, L., Valitutti, S., Baldari, C.T., 2022. Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). Int J Mol Sci 23, 14255. <https://doi.org/10.3390/ijms232214255> (IF : 6.208 – cat B)
- 13) Chesneau, B., Ivashchenko, V., Habib, C., Gaston, V., Escudié, E., Morel, G., Capri, Y., Vincent-Delorme, C., Calvas, P., Chassaing, N., Plaisancié, J., 2022. Evaluation of somatic and/or germline mosaicism in congenital malformation of the eye. Eur J Hum Genet. <https://doi.org/10.1038/s41431-022-01234-3> (IF: 5.351 – cat B)
- 14) Da Silva, A., Fléchon, A., Coquan, E., Planchamp, F., Culine, S., Murez, T., Méjean, A., Pasquier, D., Chevreau, C., Fizazi, K., Thiery-Vuillemin, A., Joly, F., 2022. How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study. Front Oncol 12, 1036190. <https://doi.org/10.3389/fonc.2022.1036190> (IF : 5.738 – cat C)

- 15) Daix, M., Angeles, M.A., Motton, S., Tanguy Le Gac, Y., Ferron, G., Martinez, A., 2022. **Peritoneal cancer index: laparoscopic evaluation of peritoneal carcinomatosis from gynecological origin.** Int J Gynecol Cancer 32, 1488–1489. <https://doi.org/10.1136/ijgc-2022-003615> (IF : 4.661 – cat B)

- 16) Dumas, P.-Y., Raffoux, E., Bérard, E., Bertoli, S., Hospital, M.-A., Heiblig, M., Desbrosses, Y., Bonmati, C., Pautas, C., Lambert, J., Orvain, C., Banos, A., Pasquier, F., Peterlin, P., Marchand, T., Uzunov, M., Frayfer, J., Turlure, P., Cluzeau, T., Jourdan, E., Himberlin, C., Tavernier, E., Villate, A., Haiat, S., Chretien, M.-L., Carre, M., Chantepie, S., Vaida, I., Wemeau, M., Chebrek, S., Guillermin, G., Guèze, R., Debarri, H., Gehlkopf, E., Laribi, K., Marcais, A., Santagostino, A., Béné, M.-C., Mineur, A., Pigneux, A., Dombret, H., Récher, C., 2022. **Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.** Leukemia. <https://doi.org/10.1038/s41375-022-01742-7> (IF : 12.833 – cat A)

- 17) Durin, L., Noël-Savina, E., Héluain, V., Mattei, P., Mazières, J., Prévot, G., 2022. **Impact of pulmonary hypertension on lung cancer management.** Respir Med Res 82, 100964. <https://doi.org/10.1016/j.resmer.2022.100964> (IF : 3.149 – cat D)

- 18) Fallara, G., Robesti, D., Nocera, L., Raggi, D., Marandino, L., Belladelli, F., Montorsi, F., Malavaud, B., Ploussard, G., Necchi, A., Martini, A., 2022. **Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.** Cancer Treat Rev 110, 102441. <https://doi.org/10.1016/j.ctrv.2022.102441> (IF : 13.608 – cat A)

- 19) Ghorbanoghli, Z., van Kouwen, M., Versluys, B., Bonnet, D., Devalck, C., Tinat, J., Januszkiewicz-Lewandowska, D., Costas, C.C., Cottureau, E., Hardwick, J.C.H., Wimmer, K., Brugieres, L., Colas, C., Vasen, H.F.A., 2022. **High yield of surveillance in patients diagnosed with constitutional mismatch repair deficiency.** J Med Genet jmg-2022-108829. <https://doi.org/10.1136/jmg-2022-108829> (IF : 5.941 – cat B)

- 20) Gimenez, L., Druel, V., Bonnet, A., Delpierre, C., Grosclaude, P., Rouge-Bugat, M.-E., 2022. **Experimental system of care coordination for the home return of patients with metastatic cancer: a survey of general practitioners.** BMC Prim Care 23, 283. <https://doi.org/10.1186/s12875-022-01891-9> (IF : 2.634 – cat C)

- 21) Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C.S., Tan, D.S.W., Lee, D.H., Misch, D., Garralda, E., Kim, D.-W., van der Wekken, A.J., Gainor, J.F., Paz-Ares, L., Liu, S.V., Kalemkerian, G.P., Houvras, Y., Bowles, D.W., Mansfield, A.S., Lin, J.J., Smoljanovic, V., Rahman, A., Kong, S., Zalutskaya, A., Louie-Gao, M., Boral, A.L., Mazières, J., 2022. **Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.** Ann Oncol 33, 1168–1178. <https://doi.org/10.1016/j.annonc.2022.08.002> (IF : 51.769 – cat A)

- 22) Hammer, A.S.B., Juul-Dam, K.L., Sandahl, J.D., Abrahamsson, J., Czogala, M., Delabesse, E., Haltrich, I., Jahnukainen, K., Kolb, E.A., Kovács, G.T., Leverger, G., Locatelli, F., Masetti, R., Noren-Nystrom, U., Raimondi, S., Rasche, M., Reinhardt, D., Taki, T., Tomizawa, D., Zeller, B., Hasle, H., Kjeldsen, E., 2022. **Hypodiploidy has Unfavorable Impact on Survival in Pediatric Acute Myeloid Leukemia:An I-BFM Study Group collaboration.** Blood Adv bloodadvances.2022008251. <https://doi.org/10.1182/bloodadvances.2022008251> (IF : 7.637 – cat B)

- 23) Hernández-Verdin, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., Uro-Coste, E., Oberic, L., Figarella-Branger, D., Chinot, O., Gauchotte, G., Taillandier, L., Marolleau, J.-P., Polivka, M., Adam, C., Ursu, R., Schmitt, A., Barillot, N., Nichelli, L., Lozano-Sánchez, F., Ibañez-Juliá, M.-J., Peyre, M., Mathon, B., Abada, Y., Charlotte, F., Davi, F., Stewart, C., de Reyniès, A., Choquet, S., Soussain, C., Houillier, C., Chapuy, B., Hoang-Xuan, K., Alentorn, A., 2022. **Molecular and clinical diversity in primary central nervous system lymphoma.** Ann Oncol S0923-7534(22)04732–9. <https://doi.org/10.1016/j.annonc.2022.11.002> (IF : 51.769 – cat A)

- 24) Johansson, P., Laguna, T., Ossowski, J., Pancaldi, V., Brauser, M., Dührsen, U., Keuneke, L., Queiros, A., Richter, J., Martín-Subero, J.I., Siebert, R., Schlegelberger, B., Küppers, R., Dürig, J., Murga Penas, E.M., Carillo-de Santa Pau, E., Bergmann, A.K., 2022. **Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker.** Clin Epigenetics 14, 148. <https://doi.org/10.1186/s13148-022-01362-z> (IF : 7.259 – cat B)

- 25) Jouglar, E., Laprie, A., Isfan, F., Dumont, B., Thebaud, E., Escande, A., Supiot, S., on behalf on the Groupe Français de Radiothérapie Pédiatrique (GFRP), 2022. **Locoregional failure after postoperative flank irradiation for nephroblastoma: Results from the French cohort of the SIOP-2001 trial.**

Pediatr Blood Cancer 69, e29950. <https://doi.org/10.1002/pbc.29950> (IF : 3.838 – cat B)

- 26) Khoshnevis, M., Brown, R., Belluco, S., Zahi, I., Maciocco, L., Bonnefont-Rebeix, C., Pillet-Michelland, E., Tranel, J., Roger, T., Nennig, C., Oudoire, P., Marcon, L., Tillement, O., Louis, C., Gehan, H., Bardiès, M., Mariani, M., Muzio, V., Meunier, J.-P., Duchemin, C., Michel, N., N'Tsiba, E., Haddad, F., Buronfosse, T., Carozzo, C., Ponce, F., 2022. **Therapeutic efficacy of 166Holmium siloxane in microbrachytherapy of induced glioblastoma in minipig tumor model.** Front Oncol 12, 923679. <https://doi.org/10.3389/fonc.2022.923679> (IF : 5.738 – cat C)
- 27) Konstantinou, M.P., Tournier, E., 2022. **Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.** Int J Dermatol 61, 1409–1411. <https://doi.org/10.1111/ijd.16269> (IF : 3.204 – cat C)
- 28) Lannes, R., Samur, M., Perrot, A., Mazzotti, C., Divoux, M., Cazaubiel, T., Leleu, X., Schavgoulidze, A., Chretien, M.-L., Manier, S., Adiko, D., Orsini-Piocelle, F., Lifermann, F., Brechignac, S., Gastaud, L., Bouscary, D., Macro, M., Cleynen, A., Mohty, M., Munshi, N., Corre, J., Avet-Loiseau, H., 2022. **In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.** J Clin Oncol JCO2101987. <https://doi.org/10.1200/JCO.21.01987> (IF : 50.717 – cat A)
- 29) Laoubi, L., Lacoffrette, M., Valsesia, S., Lenief, V., Guironnet-Paquet, A., Mosnier, A., Dubois, G., Cartier, A., Monti, L., Marvel, J., Espinosa, E., Malissen, B., Henri, S., Mondoulet, L., Sampson, H.A., Nosbaum, A., Nicolas, J.-F., Dioszeghy, V., Vocanson, M., 2022. **Epicutaneous allergen immunotherapy induces a profound and selective modulation in skin dendritic-cell subsets.** J Allergy Clin Immunol 150, 1194–1208. <https://doi.org/10.1016/j.jaci.2022.05.025> (IF : 14.29 – cat A)
- 30) Laurent, C., Cook, J.R., Yoshino, T., Quintanilla-Martinez, L., Jaffe, E.S., 2022. **Follicular lymphoma and marginal zone lymphoma: how many diseases?** Virchows Arch. <https://doi.org/10.1007/s00428-022-03432-2> (IF : 4.535 – cat C)
- 31) Lee, M.M., McDowell, G.S.V., De Vivo, D.C., Friedman, D., Berkovic, S.F., Spanou, M., Dinopoulos, A., Grand, K., Sanchez-Lara, P.A., Allen-Sharpley, M., Warman-Chardon, J., Solyom, A., Levade, T., Schuchman, E.H., Bennett, S.A.L.,

Dyment, D.A., Pearson, T.S., 2022. **The clinical spectrum of SMA-PME and in vitro normalization of its cellular ceramide profile.** Ann Clin Transl Neurol. <https://doi.org/10.1002/acn3.51687> (IF : 5.43 – cat B)

- 32) Lu, X., Vano, Y., Helleux, A., Su, X., Lindner, V., Davidson, G., Mouawad, R., Spano, J.-P., Roupret, M., Elaidi, R., Comp  rat, E., Verkarre, V., Sun, C., Chevreau, C., Bennamoun, M., Lang, H., Tricard, T., Cheng, W., Xu, L., Davidson, I., Yan, F., Fridman, W.H., Sautes-Fridman, C., Oudard, S., Malouf, G.G., 2022. **An enhancer demethylator phenotype converged to immune dysfunction and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomas.** Clin Cancer Res CCR-22-2133. <https://doi.org/10.1158/1078-0432.CCR-22-2133> (IF : 13.801 – cat A)
- 33) Marti, C., Deluche, E., Jochum, F., Bendifallah, S., Azais, H., Deidier, J., Cockenpot, V., Menoux, I., Balaya, V., Betrian, S., Chargari, C., Gouy, S., Genestie, C., Feki, A., Uzan, C., Guyon, F., Devouassoux-Shisheboran, M., Body, N., Akladios, C., Mathevet, P., Guani, B., On Behalf Of The Sfog And The Sfog Campus, null, 2022. **Management of Endometrial Cancer: French Society of Onco-Gynecology's Evaluation through a Delphi Survey.** J Clin Med 11, 6765. <https://doi.org/10.3390/jcm11226765> (IF : 4.964 – cat C)
- 34) Martinez, A., Daubisse-Marliac, L., Lacaze, J.-L., Pons-Tostivint, E., Bauvin, E., Delpierre, C., Grosclaude, P., Lamy, S., EvaSein Group, 2022. **Treatment time interval in breast cancer: A population-based study on the impact of type and number of cancer centres attended.** Eur J Cancer Care (Engl) 31, e13654. <https://doi.org/10.1111/ecc.13654> (IF : 2.328 – cat C)
- 35) Martini, A., Touzani, A., Beauval, J.-B., Ruffion, A., Olivier, J., Gasmi, A., Dariane, C., Thoulouzan, M., Barret, E., Brureau, L., Cr  hange, G., Fiard, G., Gauth  , M., Renard-Penna, R., Roubaud, G., Sargos, P., Roumigui  , M., Timsit, M.-O., Mathieu, R., Villers, A., Roupr  t, M., Fromont, G., Ploussard, G., CC-AFU, Cancerology Committee of the Association Fran  aise d'Urologie, 2022. **Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimens.** World J Urol. <https://doi.org/10.1007/s00345-022-04202-0> (IF : 3.661 – cat C)
- 36) Mazieres, J., Iadeluca, L., Shaw, A.T., Solomon, B.J., Bauer, T.M., de Marinis, F., Felip, E., Goto, Y., Kim, D.-W., Mok, T., Reisman, A., Thurm, H., Polli, A.M., Liu, G., 2022. **Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-**

small cell lung cancer. Lung Cancer 174, 146–156.
<https://doi.org/10.1016/j.lungcan.2022.11.004> (IF : 6.081 – cat B)

- 37) Montégut, C., Guillamo, J.-S., Ducray, F., Dehais, C., Cohen-Jonathan Moyal, E., Desenclos, C., Petit, A., Seizeur, R., Bekaert, L., Gaultier, C., Motuo Fotso, M.J., Blonski, M., Frenel, J.-S., Vauléon, E., Langlois, O., Noel, G., Carpentier, A.F., Di Stefano, A.L., Bronnimann, C., Figarella-Branger, D., Chinot, O., Tabouret, E., 2022. **Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study.** Cancers (Basel) 14, 5509.
<https://doi.org/10.3390/cancers14225509> (IF : 6.575 – cat B)
- 38) Neuzillet, C., Nicolle, R., Raffenne, J., Tijeras-Raballand, A., Brunel, A., Astorgues-Xerri, L., Vacher, S., Arbateraz, F., Fanjul, M., Hilmi, M., Samain, R., Klein, C., Perraud, A., Rebours, V., Mathonnet, M., Bièche, I., Kocher, H., Cros, J. & Bousquet, C., 2022. **Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma.** J Pathol 258, 408–425. <https://doi.org/10.1002/path.6011> (IF : 9.883 – cat A)
- 39) NIHR Global Health Unit on Global Surgery, COVIDSurg Collaborative, [collab : Vaysse, C.] 2022. **Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries.** Lancet 400, 1607–1617.
[https://doi.org/10.1016/S0140-6736\(22\)01846-3](https://doi.org/10.1016/S0140-6736(22)01846-3) (IF : 202.731 – cat A+)
- 40) Ouvrard, C., Métais, A., Brigot, E., Berthaud, C., Pucelle, N., Lacombe, J., Hasty, L., Chrétien, F., Bielle, F., Mokhtari, K., Cazals-Hatem, D., Lhermitte, B., Uro-Coste, E., Varlet, P., Tauziède-Espariat, A., RENOCIP-LOC, 2022. **ETV4 immunohistostaining is a sensitive and specific diagnostic biomarker for CIC-rearranged sarcoma of the central nervous system.** Histopathology 81, 852–855. <https://doi.org/10.1111/his.14796> (IF : 7.778 – cat A)
- 41) Palmieri, M., Zulato, E., Wahl, S.G.F., Guibert, N., Frullanti, E., 2022. **Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis.** Front Genet 13, 1015161. <https://doi.org/10.3389/fgene.2022.1015161> (IF : 4.772 – cat B)
- 42) Paolillo, R., Boulanger, M., Gâtel, P., Gabellier, L., De Toledo, M., Tempé, D., Hallal, R., Akl, D., Moreaux, J., Baik, H., Gueret, E., Recher, C., Sanrry, J.-E.,

- Cartron, G., Piechaczyk, M., Bossis, G., 2022. **The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias.** Haematologica 107, 2562–2575. <https://doi.org/10.3324/haematol.2021.279889> (IF : 11.047 – cat A)
- 43) Philouze, P., Malard, O., Albert, S., Badet, L., Baujat, B., Faure, F., Fuchsmann, C., Jegoux, F., Lacau-St-Guily, J., Marie, J.-P., Ramade, A., Vergez, S., Ceruse, P., Gauthier, O.J., 2022. **A New Animal Model of Laryngeal Transplantation.** J Clin Med 11, 6427. <https://doi.org/10.3390/jcm11216427> (IF : 4.964 – cat C)
- 44) Racadot, S., Thennevet, I., Ouldbey, Y., Kaminsky, M.-C., Bosset, M., Martin, L., Tao, Y., Sire, C., de Raucourt, D., Alfonsi, M., Malaurie, E., Tourani, J.-M., Fournel, P., Vauleon, E., Modesto, A., Rolland, F., Metzger, S., Pommier, P., Chabaud, S., Dussart, S., GORTEC group, 2022. **Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).** Eur J Cancer 178, 114–127. <https://doi.org/10.1016/j.ejca.2022.10.023> (IF : 10.002 – cat B)
- 45) Rousset, S., Zenou, M., Saunier, A., Varenne, F., Soler, V., Tournier, E., Legrand, L., Lachaud, L., Buffet, P., Berry, A., Delobel, P., Martin-Blondel, G., 2022. **Immune recovery-related patterns of post kala-azar dermal and ocular leishmaniasis in people living with HIV.** AIDS 36, 1819–1827. <https://doi.org/10.1097/QAD.0000000000003336> (IF : 4.632 – cat C)
- 46) Sarradin, V., Betrian, S., Chaltiel, L., Brac De La Perriere, C. & Delord, J.P., 2022. **5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).** Bull Cancer S0007-4551(22)00398–8. <https://doi.org/10.1016/j.bulcan.2022.10.004> (IF : 1.318 – cat E)
- 47) Schavgoulidze, A., Talbot, A., Perrot, A., Cazaubiel, T., Leleu, X., Manier, S., Buisson, L., Mahéo, S., Do Souto Ferreira, L., Pavageau, L., Hulin, C., Marolleau, J.-P., Voillat, L., Belhadj, K., Divoux, M., Slama, B., Brechignac, S., Macro, M., Stoppa, A.M., Sanhes, L., Orsini Piocelle, F., Fontan, J., Chretien, M.-L., Demarquette, H., Mohty, M., Avet-Loiseau, H., Corre, J., 2022. **Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.** Blood blood.2022017863. <https://doi.org/10.1182/blood.2022017863> (IF : 25.476 – cat A)
- 48) Shin, S., Solorzano, J., Liauzun, M., Pyronnet, S., Bousquet, C., Martineau, Y., 2022. **Translational alterations in pancreatic cancer: a central role for the**

integrated stress response. NAR Cancer 4, zcac031.
<https://doi.org/10.1093/narcan/zcac031> - (*cat NC*)

- 49) Sláma, J., Runnebaum, I.B., Scambia, G., Angeles, M.A., Bahrehmand, K., Kommoss, S., Fagotti, A., Narducci, F., Matylevich, O., Holly, J., Martinelli, F., Koual, M., Kopetskyi, V., El-Balat, A., Corrado, G., Căpîlna, M.E., Schröder, W., Novák, Z., Shushkevich, A., Fricová, L., Cibula, D., 2022. **Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTISS retrospective multicenter study.** Am J Obstet Gynecol S0002-9378(22)02188–3. <https://doi.org/10.1016/j.ajog.2022.11.1295> (*IF : 10.693 – cat A*)
- 50) Strojna, A.N., Kacperczyk-Bartnik, J., Angeles, M.A., Bizzarri, N., van Ramshorst, G.H., Theofanakis, C., Bilir, E., Razumova, Z., Nikolova, T., Selcuk, I., Wan, Y.-L.L., Zalewski, K., Lanner, M., Pletnev, A., Pareja, R., Fotopoulou, C., Kehoe, S., Båk, J., Ramirez, P.T., 2022. **ENYGO-IJGC scientific writing and publication course: 2021 meeting summary.** Int J Gynecol Cancer ijgc–2022–003868. <https://doi.org/10.1136/ijgc-2022-003868> (*IF : 4.661 – cat B*)
- 51) Thomas, F., Launay, M., Guitton, J., Lorient, M.-A., Boyer, J.-C., Haufroid, V., Etienne-Grimaldi, M.-C., Royer, B., GPCO-UNICANCER Group, 2022. **Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!** Clin Pharmacol Ther. <https://doi.org/10.1002/cpt.2772> (*IF : 6.903 – cat B*)
- 52) Trecourt, A., Donzel, M., Fontaine, J., Ghesquières, H., Jallade, L., Antherieu, G., Laurent, C., Mauduit, C., Traverse-Glehen, A., 2022. **Plasticity in Classical Hodgkin Composite Lymphomas: A Systematic Review.** Cancers (Basel) 14, 5695. <https://doi.org/10.3390/cancers14225695> (*IF : 6.575 – cat B*)
- 53) Villeneuve, T., Pontier, S., Prévot, G., Guibert, N., Chevreau, C., Rochaix, P., Courtade-Saidi, M., 2022. **EBUS-TBNA for the diagnosis of primary pulmonary artery sarcoma.** Respir Med Res 83, 100974. <https://doi.org/10.1016/j.resmer.2022.100974> (*IF : 3.149 – cat D*)
- 54) Watts, J.M., Baer, M.R., Yang, J., Prebet, T., Lee, S., Schiller, G.J., Dinner, S.N., Pigneux, A., Montesinos, P., Wang, E.S., Seiter, K.P., Wei, A.H., De Botton, S., Arnan, M., Donnellan, W., Schwarzer, A.P., Récher, C., Jonas, B.A., Ferrell, P.B., Marzac, C., Kelly, P., Sweeney, J., Forsyth, S., Guichard, S.M., Brevard, J., Henrick, P., Mohamed, H., Cortes, J.E., 2022. **Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.** Lancet Haematol S2352-

3026(22)00292–7. [https://doi.org/10.1016/S2352-3026\(22\)00292-7](https://doi.org/10.1016/S2352-3026(22)00292-7) (IF : 30.153 – cat A)

55) You, B., Bolze, P.-A., Lotz, J.-P., Massardier, J., Gladieff, L., Floquet, A., Hajri, T., Descargues, P., Langlois-Jacques, C., Bin, S., Villeneuve, L., Roux, A., Alves-Ferreira, M., Grazziotin-Soares, D., Dherret, G., Gerentet, C., Rousset, P., Freyer, G., Golfier, F., 2022. **Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.** *Gynecol Oncol* 168, 62–67. <https://doi.org/10.1016/j.ygyno.2022.11.005> (IF : 5.304 – cat B)

56) Zangarelli, C., Arnaiz, O., Bourge, M., Gorrichon, K., Jaszczyszyn, Y., Mathy, N., Escoriza, L., Betermier, M., Regnier, V., 2022. **Developmental timing of programmed DNA elimination in *Paramecium tetraurelia* recapitulates germline transposon evolutionary dynamics.** *Genome Res* gr.277027.122. <https://doi.org/10.1101/gr.277027.122> (IF : 9.438 – cat A)



